Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. (Q45937867)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. |
scientific article |
Statements
1 reference
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. (English)
1 reference
1 reference
Matija Tomsic
1 reference
Petra Bohanec Grabar
1 reference
Blaz Rozman
1 reference
Dusan Logar
1 reference
Dasa Suput
1 reference
Tina Trdan
1 reference
Lucija Peterlin Masic
1 reference
Ales Mrhar
1 reference
Vita Dolzan
1 reference
6 July 2009
1 reference
1 reference
37
1 reference
2061-2068
1 reference
10
1 reference
Identifiers
1 reference
1 reference